Faron Pharmaceuticals Oy (HEL:FARON)

Market Cap	238.79M
Revenue (ttm)	n/a
Net Income (ttm)	-30.95M
Shares Out	n/a
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	317,373
Average Volume	418,149
Open	2.215
Previous Close	2.200
Day's Range	2.120 - 2.215
52-Week Range	1.656 - 3.345
Beta	1.08
RSI	38.29
Earnings Date	Aug 27, 2025

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 25
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: FARON